AbbVie, Medicines Patent Pool deal

The Medicines Patent Pool received non-exclusive rights from AbbVie to sublicense, reformulate, develop, commercialize and manufacture lopinavir and ritonavir fixed-dose combination generics to treat and prevent pediatric HIV infection. The agreement covers 102 countries and allows manufacture and commercialization in countries where AbbVie does not hold patents. AbbVie markets Kaletra lopinavir/ritonavir worldwide to treat HIV infection in adults and children. Kaletra is a combination of the HIV protease inhibitor lopinavir plus ritonavir, which inhibits the cytochrome P450 3A4 ( CYP3A4)-mediated metabolism of lopinavir. ...